This site uses cookies to ensure the best viewing experience for our readers.
Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

Brief

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023

CTech | 12:10  24.03.2019
Denmark’s Novo Nordisk has settled a U.S. patent litigation case with Teva Pharmaceutical Industries Ltd. for its brand drug Victoza, Novo Nordisk announced last week. Teva first filed an application for a generic version of the drug with the U.S. Food and Drug Administration in early 2017.

Under the settlement agreement, Teva will be able to sell a generic version of the drug, which is used to stabilize blood sugar and reduce cardiovascular risk in type 2 diabetics, as of December 2023.

Teva. Photo: Bloomberg Teva. Photo: Bloomberg Teva. Photo: Bloomberg

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS